Imiquimod for Actinic Keratosis: Systematic Review and Meta-Analysis
Imiquimod for Actinic Keratosis: Systematic Review and Meta-Analysis
About this item
Full title
Author / Creator
Publisher
Danvers, MA: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
Danvers, MA: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Benefit and harm associated with treating actinic keratosis (AK) with the immune response modifier imiquimod was assessed using published randomized-controlled trials. Five randomized double-blind trials lasted 12–16 weeks and treated 1,293 patients. Complete clearance occurred in 50% of patients treated with imiquimod, compared to 5% treated with...
Alternative Titles
Full title
Imiquimod for Actinic Keratosis: Systematic Review and Meta-Analysis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_210352381
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_210352381
Other Identifiers
ISSN
0022-202X
E-ISSN
1523-1747
DOI
10.1038/sj.jid.5700264
